Holen Sie sich die Stockscreener-App
2.85
9.52%
-0.30
Handel nachbörslich:
2.85
Schlusskurs vom Vortag:
$3.15
Offen:
$3.19
24-Stunden-Volumen:
132.79K
Relative Volume:
2.34
Marktkapitalisierung:
$84.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.74M
KGV:
-0.1517
EPS:
-18.7859
Netto-Cashflow:
$-15.75M
1W Leistung:
-32.78%
1M Leistung:
-52.58%
6M Leistung:
-42.07%
1J Leistung:
+19.75%
1-Tages-Spanne:
$2.70
$3.23
1-Wochen-Bereich:
$2.70
$4.2599
52-Wochen-Spanne:
$1.87
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Firmenname
Dogwood Therapeutics Inc
Sektor
Branche
Telefon
(866) 620-8655
Adresse
44 MILTON AVENUE, ALPHARETTA
Vergleichen Sie DWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
2.85 | 93.64M | 0 | -24.74M | -15.75M | -18.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
Will Dogwood Therapeutics Inc. stock continue upward momentum2025 Year in Review & Stepwise Entry and Exit Trade Signals - ulpravda.ru
Will Dogwood Therapeutics Inc. stock recover faster than market2025 Major Catalysts & Capital Efficiency Focused Ideas - ulpravda.ru
Will Dogwood Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - ulpravda.ru
Why Dogwood Therapeutics Inc. stock is trending among retail tradersInsider Selling & Weekly Setup with High ROI Potential - ulpravda.ru
Can Dogwood Therapeutics Inc. stock hit record highs againJuly 2025 WrapUp & Fast Entry High Yield Tips - ulpravda.ru
What technical charts say about Dogwood Therapeutics Inc. stock2025 Performance Recap & Daily Entry Point Trade Alerts - ulpravda.ru
Momentum Shift: Will Dogwood Therapeutics Inc. stock recover faster than market2025 Major Catalysts & Capital Efficiency Focused Ideas - ulpravda.ru
How sustainable is Dogwood Therapeutics Inc. stock dividend payout2025 Earnings Surprises & Accurate Technical Buy Alerts - ulpravda.ru
Can Dogwood Therapeutics Inc. stock rebound after recent weaknessEarnings Season Recap & Add These Before Everyone Else Does - bollywoodhelpline.com
DWTX: Positive Interim Results for Halneuron Phase 2b Trial in CINP Raising Valuation to 15 - Research Tree
Aug Chart Watch: What hedge fund activity signals for Dogwood Therapeutics Inc stockProfit Target & Stock Portfolio Risk Management - moha.gov.vn
DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15 - Zacks Small Cap Research
Trading Recap: Can Dogwood Therapeutics Inc stock hit record highs againJuly 2025 Final Week & Risk Managed Investment Entry Signals - moha.gov.vn
What date does Dogwood Therapeutics, Inc's (DWTX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Aug Big Picture: Will Dogwood Therapeutics Inc stock continue upward momentumTrade Risk Assessment & Safe Entry Point Alerts - moha.gov.vn
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc? - Benzinga
Halneuron Shows Pain Relief Separation In Interim Phase 2b Trial - Nasdaq
CKLIFE SCIENCES: Positive Results Obtained from Interim Analysis of Halneuron Phase 2b Study - AASTOCKS.com
DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence - Stocktwits
Dogwood Therapeutics stock plummets after Phase 2b interim results By Investing.com - Investing.com South Africa
Dogwood Therapeutics stock plummets after Phase 2b interim results - Investing.com
Dogwood Therapeutics reports positive interim phase 2b results in chemotherapy-induced neuropathic pain - marketscreener.com
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron - marketscreener.com
Dogwood reports positive interim results for pain treatment By Investing.com - Investing.com South Africa
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain - The Manila Times
Dogwood Therapeutics Announces Positive Interim Phase 2b - GlobeNewswire
Can Dogwood Therapeutics Inc. stock sustain institutional interestQuarterly Profit Report & Smart Swing Trading Alerts - ulpravda.ru
Why retail investors favor Dogwood Therapeutics Inc. stockJuly 2025 Big Picture & Safe Swing Trade Setups - Улправда
Published on: 2025-12-21 10:22:42 - moha.gov.vn
Is Dogwood Therapeutics Inc. stock a bargain at current levelsJuly 2025 Action & Weekly Setup with ROI Potential - Улправда
Why Dogwood Therapeutics Inc. stock is recommended by analystsJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - Улправда
What hedge fund activity signals for Dogwood Therapeutics Inc. stock2025 Sector Review & Smart Swing Trading Alerts - DonanımHaber
Stock Market Recap: Why Dogwood Therapeutics Inc. stock is recommended by analysts2025 Market Overview & Safe Capital Preservation Plans - Улправда
Aug Macro: Can Dogwood Therapeutics Inc. stock sustain institutional interest2025 Top Gainers & Safe Entry Trade Reports - Улправда
Dogwood Therapeutics Earnings Notes - Trefis
Can Dogwood Therapeutics Inc. stock outperform in 2025 bull market2025 Risk Factors & Low Drawdown Momentum Ideas - Newser
Why Dogwood Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Daily Technical Forecast Reports - Newser
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 - ACCESS Newswire
Dogwood Therapeutics (Nasdaq: DWTX) files synthetic Halneuron IP, eyes 2045 exclusivity - Stock Titan
Dogwood Therapeutics (DWTX) Stock Analysis Report | Financials & Insights - Benzinga
Dogwood Therapeutics Inc enters equity distribution agreement with Northland SecuritiesSEC filing - marketscreener.com
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight - GlobeNewswire Inc.
[Form 4] Dogwood Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dogwood Therapeutics: Clinical Readout Looms As A Potential Game-Changer - RTTNews
What Institutional Trends Suggest About Pearl Polymers Limiteds DirectionSupport Zone Identification & High Return Capital Strategies - earlytimes.in
What analysts say about Dogwood Therapeutics Inc stockStock Valuation Metrics & Affordable Investment Portfolio - earlytimes.in
Dogwood Therapeutics Approves Equity Plan Amid Business Merger - The Globe and Mail
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge - MSN
Finanzdaten der Dogwood Therapeutics Inc-Aktie (DWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):